{"id":8533,"date":"2024-04-26T14:30:40","date_gmt":"2024-04-26T14:30:40","guid":{"rendered":"http:\/\/hnetalk.com\/provider\/?p=8533"},"modified":"2024-04-29T18:23:18","modified_gmt":"2024-04-29T18:23:18","slug":"formulary-may-2024","status":"publish","type":"post","link":"http:\/\/hnetalk.com\/provider\/formulary-may-2024\/","title":{"rendered":"Formulary: May 2024"},"content":{"rendered":"<p>Health New England\u2019s formularies are located at <a href=\"http:\/\/healthnewengland.org\/\"><strong>healthnewengland.org<\/strong><\/a><a href=\"http:\/\/healthnewengland.org\/\">.<\/a> At the top of the page, use the \u201cFind A Drug\u201d tool.<\/p>\n<p>&nbsp;<\/p>\n<table>\n<tbody>\n<tr>\n<td width=\"94\"><strong>Medication<\/strong><\/td>\n<td width=\"464\"><strong>Changes<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Abiraterone<\/td>\n<td width=\"464\">edited policy to clarify that the 500mg tabs are excluded and that 250mg are the alternative, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">Alosetron<\/td>\n<td width=\"464\">added max dose restriction, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">Arcalyst<\/td>\n<td width=\"464\">added max dose restriction, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Arikayce<\/td>\n<td width=\"464\">&nbsp;<\/p>\n<p>added max dose restriction, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Bosulif<\/td>\n<td width=\"464\">updated age limitation to 1 year and older for chronic phase CML, added 50mg strength, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Bylvay<\/td>\n<td width=\"464\">&nbsp;<\/p>\n<p>added new indication for alagille syndrome, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Cayston<\/td>\n<td width=\"464\">&nbsp;<\/p>\n<p>added specialist criteria and max dose restriction, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Cholbam<\/td>\n<td width=\"464\">changed initial duration of approval to 6 months, added quantity limits, updated<\/p>\n<p>references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">Cosentyx 125mg\/5ml<\/td>\n<td width=\"464\">added new IV formulation to criteria<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Enbrel CM<\/td>\n<td width=\"464\">updated age limitation to 2 years and older for psoriatic arthritis, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Ilaris<\/td>\n<td width=\"464\">added new indication of gout flares, added max dosing limitations, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Livmarli<\/td>\n<td width=\"464\">&nbsp;<\/p>\n<p>updated age limitation to 3 months and older, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">Medical Necessity CM<\/td>\n<td width=\"464\">added clarifying compound criteria, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Nexavar sorafenib<\/td>\n<td width=\"464\">added desmoid tumors as covered indication per NCCN guidelines, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Reditrex CM<\/td>\n<td width=\"464\">&nbsp;<\/p>\n<p>Policy discontinued as product discontinued.<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Rinvoq CM<\/td>\n<td width=\"464\">minor grammatical changes, altered initial approval duration, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Rozlytrek<\/td>\n<td width=\"464\">updated age to 1 month and older for solid tumors, added new strength to policy, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Tarpeyo<\/td>\n<td width=\"464\">added lab result requirements, added that Tarpeyo is not to be used with Filspari,<\/p>\n<p>updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Vancomycin 250mg<\/td>\n<td width=\"464\">added requirement to step through 125mg capsules first, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">Vocabria<\/td>\n<td width=\"464\">updated age limitation to 12 and older, updated references and dates<\/td>\n<\/tr>\n<tr>\n<td width=\"94\">&nbsp;<\/p>\n<p>Xalkori<\/td>\n<td width=\"464\">added new pellet formulation to criteria, updated ql based on indication, updated references and dates<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<ul>\n<li>The following Clinical Review Criteria Policies are <strong>new<\/strong>:<\/li>\n<\/ul>\n<table>\n<tbody>\n<tr>\n<td width=\"112\">Akeega<\/td>\n<\/tr>\n<tr>\n<td width=\"112\">Augtyro<\/td>\n<\/tr>\n<tr>\n<td width=\"112\">Daybue<\/td>\n<\/tr>\n<tr>\n<td width=\"112\">Filspari<\/td>\n<\/tr>\n<tr>\n<td width=\"112\">Fruzaqla<\/td>\n<\/tr>\n<tr>\n<td width=\"112\">Joenja<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Health New England\u2019s formularies are located at healthnewengland.org. At the top of the page, use the \u201cFind A Drug\u201d tool. &nbsp; Medication Changes &nbsp; Abiraterone edited policy to clarify that the 500mg tabs are excluded and that 250mg are the alternative, updated references and dates Alosetron added max dose restriction, updated references and dates Arcalyst [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[92],"tags":[],"class_list":["post-8533","post","type-post","status-publish","format-standard","hentry","category-provider-newsletter"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p6ZZHB-2dD","_links":{"self":[{"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/posts\/8533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/comments?post=8533"}],"version-history":[{"count":5,"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/posts\/8533\/revisions"}],"predecessor-version":[{"id":8552,"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/posts\/8533\/revisions\/8552"}],"wp:attachment":[{"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/media?parent=8533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/categories?post=8533"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/hnetalk.com\/provider\/wp-json\/wp\/v2\/tags?post=8533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}